Clinical Trials Logo

Dystrophic Epidermolysis Bullosa clinical trials

View clinical trials related to Dystrophic Epidermolysis Bullosa.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05529134 Not yet recruiting - Clinical trials for Dystrophic Epidermolysis Bullosa

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Start date: April 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A double-blind, randomized, intra-patient placebo- controlled, multiple dose study of PTW-002 evaluating safety, proof of mechanism, preliminary efficacy, and systemic exposure in patients with Dominant Dystrophic Epidermolysis Bullosa (DDEB) or Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene. Up to two RDEB patients 4 to 17 years of age and up to 6 DDEB patients 4 years of age and older will be enrolled.

NCT ID: NCT04173650 Not yet recruiting - Clinical trials for Dystrophic Epidermolysis Bullosa

MSC EVs in Dystrophic Epidermolysis Bullosa

Start date: April 2024
Phase: Phase 1/Phase 2
Study type: Interventional

INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, non randomized, multi-center, ascending dose, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.